UAE’s Gulf Pharmaceutical Industries (Julphar) is set to resume its exports to Bahrain and Kuwait after the lifting of restrictions earlier imposed on its products.
The pharmaceuticals giant said on Tuesday that the sale of its 100 manufactured drugs in the two Gulf states will resume following a “successful inspection” at its facilities by the health authorities.
According to Dr. Essam Farouk, chief executive officer at Julphar, the resumption of sales marks their re-entry in all markets across the Gulf Cooperation Council (GCC) region.
“Ensuring patients are able to access the products and treatment they need is of utmost importance to us and this resumption of sales marks the relaunch of our products in all GCC markets,” Farouk said in a statement.
The sales of operations of one of the region’s largest drug manufacturers were impacted last year following the suspension of its exports to the two states, as well as in Saudi Arabia and Oman. The ban was imposed on the company’s products for failing to meet standards.
The company resumed its exports to Oman in March. In late April, Julphar announced it would also resume its sale in Saudi Arabia.
(Writing by Cleofe Maceda; editing by Seban Scaria)
#UAE #JULPHAR #PHARMA #BAHRAIN #KUWAIT
Disclaimer: This article is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Read our full disclaimer policy here
© ZAWYA 2020